Page Image

Breast Cancers Today

Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.

HER2
Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

A combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) has demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with standard-of-care chemotherapy plus pembrolizumab in patients with previously untreated PD-L1+ metastatic triple-negative breast cancer, according to topline results from the phase III ASCENT-04/KEYNOTE-D19 trial.

Advertisement

Latest News

Expert Interviews

Advertisement
Editorial Board

Advertisement